We narrowed to 8,680 results for: aav

#26971-AAV1

Ready-to-use AAV1 particles produced from pAAV-CaMKIIa-eNpHR 3.0-EYFP (#26971). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-eNpHR 3.0-EYFP plasmid DNA. CaMKIIa-driven eNpHR 3.0-EYFP for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Feb. 14, 2018

Academic Institutions and Nonprofits only

#218874-AAV5

Ready-to-use AAV5 particles produced from pGP-AAV-syn-iGABASnFR2-WPRE (#218874). In addition to the viral particles, you will also receive purified pGP-AAV-syn-iGABASnFR2-WPRE plasmid DNA. Syn-driven expression of the improved GABA sensor iGABASnFR2 (positive change in fluorescence). These AAV preparations are suitable purity for injection into animals.

GENIE Project

Kolb et al eLife. 2026 Mar 18;14:RP108319. doi: 10.

Sept. 27, 2024

Academic Institutions and Nonprofits only

#59462-AAV8

Ready-to-use AAV8 particles produced from pAAV-CAG-tdTomato (codon diversified) (#59462). In addition to the viral particles, you will also receive purified pAAV-CAG-tdTomato (codon diversified) plasmid DNA. CAG-driven tdTomato expression control. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Jan. 26, 2021

Academic Institutions and Nonprofits only

#58880-AAV8

Ready-to-use AAV8 particles produced from pAAV-Syn-ChR2(H134R)-GFP (#58880). In addition to the viral particles, you will also receive purified pAAV-Syn-ChR2(H134R)-GFP plasmid DNA. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Boyden et al Nat Neurosci. 2005 Sep . 8(9):1263-8.

Oct. 13, 2017

Academic Institutions and Nonprofits only

#198511-AAV1

Ready-to-use AAV1 particles produced from pAAV_hSyn-DIO-PdCO-mScarlet-WPRE (#198511). In addition to the viral particles, you will also receive purified pAAV_hSyn-DIO-PdCO-mScarlet-WPRE plasmid DNA. Syn-driven Cre-dependent expression of optimized PdCO in frame with mScarlet. These AAV preparations are suitable purity for injection into animals.

Ofer Yizhar

Wietek et al Nat Methods. 2024 May 29. doi: 10.1038/s

Sept. 27, 2024

Academic Institutions and Nonprofits only

#218871-AAV5

Ready-to-use AAV5 particles produced from pGP-AAV-GFAP-iGABASnFR2-WPRE (#218871). In addition to the viral particles, you will also receive purified pGP-AAV-GFAP-iGABASnFR2-WPRE plasmid DNA. GFAP-driven expression of the improved GABA sensor iGABASnFR2 (positive change in fluorescence). These AAV preparations are suitable purity for injection into animals.

GENIE Project

Kolb et al eLife. 2026 Mar 18;14:RP108319. doi: 10.

Sept. 27, 2024

Academic Institutions and Nonprofits only

#137119-AAV8

Ready-to-use AAV8 particles produced from pAAV-EF1a-Con/Fon-GCaMP6M (#137119). In addition to the viral particles, you will also receive purified pAAV-EF1a-Con/Fon-GCaMP6M plasmid DNA. EF1a-driven, Cre and Flp-dependent expression of GCaMP6M. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

Sept. 24, 2020

Academic Institutions and Nonprofits only

#26975-AAV5

Ready-to-use AAV5 particles produced from pAAV-CaMKIIa-hChR2(H134R)-mCherry (#26975). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-hChR2(H134R)-mCherry plasmid DNA. CaMKIIa-driven, humanized channelrhodopsin H134R mutant fused to mCherry for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Feb. 15, 2018

Academic Institutions and Nonprofits only

#50472-AAV5

Ready-to-use AAV5 particles produced from pAAV-GFAP-HA-rM3D(Gs)-IRES-mCitrine (#50472). In addition to the viral particles, you will also receive purified pAAV-GFAP-HA-rM3D(Gs)-IRES-mCitrine plasmid DNA. GFAP-driven HA-tagged rM3D(Gs) and bicistronic mCitrine expression, for chemogenetic excitation. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

Jan. 6, 2022

Academic Institutions and Nonprofits only

#50467-AAV8

Ready-to-use AAV8 particles produced from pAAV-CaMKIIa-HA-hM4D(Gi)-IRES-mCitrine (#50467). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-HA-hM4D(Gi)-IRES-mCitrine plasmid DNA. CaMKIIa-driven HA-tagged hM4D(Gi) and bicistronic mCitrine expression, for chemogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

May 29, 2020

Academic Institutions and Nonprofits only

#107738-AAV2

Ready-to-use AAV2 particles produced from pAAV-hSyn-Cre-P2A-dTomato (#107738). In addition to the viral particles, you will also receive purified pAAV-hSyn-Cre-P2A-dTomato plasmid DNA. hSyn-driven expression of Cre and dTomato (physically separate). These AAV preparations are suitable purity for injection into animals.

Rylan Larsen

Feb. 25, 2021

Academic Institutions and Nonprofits only

#203840-AAV8

Ready-to-use AAV8 particles produced from pAAV-hSyn-Kir2.1WT-2A-mScarlet-KASH (#203840). In addition to the viral particles, you will also receive purified pAAV-hSyn-Kir2.1WT-2A-mScarlet-KASH plasmid DNA. hSyn-driven expression of Kir2.1 and mScarlet-KASH. These AAV preparations are suitable purity for injection into animals.

Ivo Spiegel

Roethler et al Neuron. 2023 Jun 20:S0896-6273(23)00399-

Oct. 8, 2025

Academic Institutions and Nonprofits only

#207997-AAV5

Ready-to-use AAV5 particles produced from pAAV hSyn-fDIO-taCasp3-TEVp (#207997). In addition to the viral particles, you will also receive purified pAAV hSyn-fDIO-taCasp3-TEVp plasmid DNA. hSyn-driven, Flp-dependent, expression of taCasp3-TEVp. These AAV preparations are suitable purity for injection into animals.

Kazunari Miyamichi

Goto et al Neuron. 2025 Feb 17:S0896-6273(25)00041-

Nov. 13, 2025

Academic Institutions and Nonprofits only

#99039-AAV5

Ready-to-use AAV5 particles produced from pAAV-CamKII-ArchT-GFP (PV2527) (#99039). In addition to the viral particles, you will also receive purified pAAV-CamKII-ArchT-GFP (PV2527) plasmid DNA. CaMKII-driven ArchT-GFP expression for optogenetic inhibition.

Edward Boyden

Han et al Front Syst Neurosci. 2011;5:18. Epub 201

Feb. 21, 2018

Academic Institutions and Nonprofits only

#101060-AAV1

Ready-to-use AAV1 particles produced from pAAV_hsyn_NES-his-CaMPARI2-WPRE-SV40 (#101060). In addition to the viral particles, you will also receive purified pAAV_hsyn_NES-his-CaMPARI2-WPRE-SV40 plasmid DNA. Synapsin-driven, photoconvertible (irreversible green-to-red) calcium integrator his-tagged CaMPARI2. These AAV preparations are suitable purity for injection into animals.

Eric Schreiter

Moeyaert et al Nat Commun. 2018 Oct 25;9(1):4440. doi:

July 23, 2018

Academic Institutions and Nonprofits only

#137155-AAV8

Ready-to-use AAV8 particles produced from pAAV-nEF-Con/Fon-iC++-EYFP (#137155). In addition to the viral particles, you will also receive purified pAAV-nEF-Con/Fon-iC++-EYFP plasmid DNA. nEF-driven, Cre and Flp-dependent expression of chloride-conducting channelrhodopsin iC++-EYFP for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

Dec. 1, 2020

Academic Institutions and Nonprofits only

#104489-AAV1

Ready-to-use AAV1 particles produced from pGP-AAV-syn-jGCaMP7b-WPRE (#104489). In addition to the viral particles, you will also receive purified pGP-AAV-syn-jGCaMP7b-WPRE plasmid DNA. Syn-driven jGCaMP7b calcium sensor. jGCaMP7b exhibits the brightest resting fluorescence of the jGCaMP7 variants, and can be used for imaging of small neuronal processes. These AAV preparations are suitable purity for injection into animals.

Douglas Kim, GENIE Project

Dana et al Nat Methods. 2019 Jul;16(7):649-657. doi

June 7, 2018

Academic Institutions and Nonprofits only

#26968-AAV1

Ready-to-use AAV1 particles produced from pAAV-Ef1a-DIO ChETA-EYFP (#26968). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO ChETA-EYFP plasmid DNA. EF1a-driven, Cre-dependent, ChETA fused to EYFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Gunaydin et al Nat Neurosci. 2010 Mar;13(3):387-92. doi

Feb. 21, 2018

Academic Institutions and Nonprofits only

#234437-AAV1

Ready-to-use AAV1 particles produced from pAAV-syn-iGluSnFR4s-NGR-WPRE (#234437). In addition to the viral particles, you will also receive purified pAAV-syn-iGluSnFR4s-NGR-WPRE plasmid DNA. Syn-driven, iGluSnFR4s-NGR sensor expression. These AAV preparations are suitable purity for injection into animals.

GENIE Project

Aggarwal et al Nat Methods. 2026 Feb;23(2):417-425. doi

Oct. 23, 2025

Academic Institutions and Nonprofits only

#83896-AAV1

Ready-to-use AAV1 particles produced from pAAV-hDlx-GiDREADD-dTomato-Fishell-5 (#83896). In addition to the viral particles, you will also receive purified pAAV-hDlx-GiDREADD-dTomato-Fishell-5 plasmid DNA. hDlx-driven expression of Gi-DREADD and nuclear localized dTomato (physically separate). These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Dimidschstein et al Nat Neurosci. 2016 Oct 31. doi: 10.1038/

Aug. 28, 2020

Academic Institutions and Nonprofits only